Status:
COMPLETED
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.
Eligibility Criteria
Inclusion
- Patient is able to provide written informed consent before beginning any study related procedures
- Patient has a documented clinical diagnosis of schizophrenia
- Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion
- Patients with a history of non-compliance as judged by the study investigator
- Patients with a known lack of response to previous treatment with quetiapine
- Patients who have participated in another drug study within 4 weeks prior to enrollment into this study
- Patients who have previously participated in this study or study D1444C00132
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
535 Patients enrolled
Trial Details
Trial ID
NCT00085891
Start Date
June 1 2004
End Date
September 1 2005
Last Update
March 25 2009
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States
2
Research Site
Cerritos, California, United States
3
Los Angeles, California, United States
4
Research Site
San Diego, California, United States